Expression level and differential JAK2-V617F-binding of the adaptor protein Lnk regulates JAK2-mediated signals in myeloproliferative neoplasms

Blood

Volumn 116, Issue 26, 2010, Pages 5961-5971

  Baran Marszak, Fanny ^a,b   Magdoud, Hajer ^b,c   Desterke, Christophe ^b   Alvarado, Anabell ^b,c   Roger, Claudine ^a   Harel, Stéphanie ^a   Mazoyer, Elizabeth ^a   Cassinat, Bruno ^d   Chevret, Sylvie ^d   Tonetti, Carole ^e   Giraudier, Stéphane ^e   Fenaux, Pierre ^a   Cymbalista, Florence ^a   Varin Blank, Nadine ^b,c   Le Bousse Kerdilès, Marie Caroline ^b   Kiladjian, Jean Jacques ^b,c,d   Velazquez, Laura ^b,c  

^a AVICENNE HOSPITAL   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS 13   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; JANUS KINASE 2; PROTEIN LNK; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MEGAKARYOCYTE; MYELOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN INTERACTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; THROMBOCYTE; UPREGULATION;

EID: 78650279826     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-12-256768     Document Type: Article

References (38)

1. Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med. 2008;355(23):2452-2466.
2. Baxter JE, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054-1061.
3. James C, Ugo V, Le Couédic J-P, et al. Aunique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144-1148. (Pubitemid 40663494)
4. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-1790. (Pubitemid 40570926)
5. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387-397.
6. Zhao R, Xing S, Li Z, et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem. 2005;280(24):22788-22792.
7. Cazzola M, Skoda RC. Gain of function, loss of control-a molecular basis for chronic myeloproliferative disorders. Haematologica. 2005;90(7):871-874.
8. Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;108(10):3472-3476.
9. Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3(7): e270.
10. Rudd EC. Lnk adaptor: novel negative regulator of B cell lymphopoiesis. Science STKE. 2001; PE1.
11. Bersenev A, Wu C, Balcerek J, Tong W. Lnk controls mouse hematopoietic stem cell self-renewal and quiescence through direct interactions with JAK2. J Clin Invest. 2008;118(8):2832-2844.
12. Buza-Vidas N, Antonchuk J, Qian H, et al. Cytokines regulate postnatal hematopoietic stem cell expansion: opposing roles of thrombopoietin and LNK. Genes Dev. 2006;20(15):2018-2023.
13. Ema H, Sudo K, Seita J, et al. Quantification of self-renewal capacity in single hematopoietic stem cells from normal and Lnk-deficient mice. Develop Cell. 2005;8(6):907-914.
14. Seita J, Ema H, Ooehara J, et al. Lnk negatively regulates self-renewal of hematopoietic stem cells by modifying thrombopoietin-mediated signal transduction. Proc Natl Acad Sci U S A. 2007;104(7):2349-2354.
15. Takizawa H, Eto K, Yoshikawa A, Nakauchi H, Takatsu K, Takaki S. Growth and maturation of megakaryocytes is regulated by Lnk/Sh2b3 adaptor protein through crosstalk between cytokineand integrin-mediated signals. Exp Hematol. 2008;36(7):897-906.
16. Tong W, Lodish FH. Lnk inhibits Tpo-mpl signaling and Tpo-mediated megakaryocytopoiesis. J Exp Med. 2004;200(5):569-580.
17. Tong W, Lodish FH. Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways. Blood. 2005;105(12):4604-4612.
18. Gery S, Gueller S, Chumakova K, Kawamata N, Liu L, Koeffler HP. Adaptor protein Lnk negatively regulates the mutant MPL, MPLW515L associated with myeloproliferative disorders. Blood. 2007;110(9):3360-3364.
19. Gery S, Qi C, Gueller S, Hongtao X, Tefferi A, Koeffler HP. Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F. J Leuk Biol. 2009;85(6):957-965.
20. Takaki S, MoritaH, Tezuka Y, Takatsu K. Enhanced hematopoiesis by hematopoietic progenitor cells lacking intracellular adaptor protein, Lnk. J Exp Med. 2002;195(2):151-160.
21. Velazquez L, Cheng MA, Fleming EH, et al. Cytokine signaling and hematopoietic homeostasis are disrupted in Lnk-deficient mice. J Exp Med. 2002;195(12):1599-1611.
22. Kiladjian JJ, Cassinat B, Turlure P, et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon α-2a. Blood. 2006;108(6):2037-2040.
23. Chaligne R, James C, Tonetti C, et al. Evidence for MPLW515L/K mutations in hematopoietic stem cells in primitive myelofibrosis. Blood. 2007;110(10):3735-3743.
24. Simon C, Dondi E, Chaix A, et al. Lnk adaptor protein down-regulates specific Kit-induced signaling pathways in primary mast cells. Blood. 2008;112(10):4039-4047.
25. Oh ST, Simonds EF, Jones C, et al. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood. 2010;116(6):988-992.
26. Ishiguro A, Suzuki Y, Mito M, et al. Elevation of serum thrombopoietin precedes thrombocytosis in acute infections. Br J Haematol. 2002;116(3):612-618.
27. Kaushansky K. The molecular mechanisms that control thrombopoiesis. J Clin Invest. 2005;115(12):3339-3347.
28. Kurzer JH, Saharinen P, Silvennoinen O, Carter-Su C. Binding of SH2-B family members within a potential regulatory region maintains JAK2 in an active state. Mol Cell Biol. 2006;26(17):6381-6394.
29. Maures TJ, Kurzer JH, Carter-Su C. SH2B1 (SH2-B) and JAK2: a multifunctional adaptor protein and kinase made for each other. Trends Endocrinol Metab. 2006;18(1):38-45.
30. Gery S, Gueller S, Nowak V, Sohn J, Hofman WK, Koeffler HP. Expression of the adaptor protein Lnk in leukemia cells. Exp Hematol. 2009;37(5):585-592.
31. Kent DG, Dykstra BJ, Cheyne J, Ma E, Eaves CJ. Steel factor coordinately regulates the molecular signature and biologic function of hematopoietic stem cells. Blood. 2008;112(3):560-567.
32. Croker BA, Kiu H, Nicholson SE. SOCS regulation of the JAK/STAT signalling pathway. Semin Cell Develop Biol. 2008;19(4):414-422.
33. Quentmeier H, Geffers R, Jost E, et al. SOCS2: inhibitor of JAK2V617F-mediated signal transduction. Leukemia. 2008;22(12):2169-2175.
34. Hookham MB, Elliott J, Suessmuth Y, et al. The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3. Blood. 2007;109(11):4924-4929.
35. Rui L, Gunter DR, Herrington J, Carter-Su C. Differential binding to and regulation of JAK2 by the SH2 domain and N-terminal region of SH2-Bbeta. Mol Cell Biol. 2000;20(9):3168-3177.
36. Delhommeau F, DuPont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009;360(22):2289-2301.
37. Delhommeau F, DuPont S, Tonetti C, et al. Evidence that the JAK2 G1849T (V617) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis. Blood. 2007;109(1):71-77.
38. Bersenev A, Wu C, Balcerek J, et al. Lnk constrains myeloproliferative diseases in mice. J Clin Invest. 2010;120(6):2058-22069.